The trial conducted by Legacy Health System aims to evaluate a novel insulin and glucagon delivery system that could significantly enhance glycemic control in Type 1 Diabetes patients. The integration of glucagon with insulin therapy represents a potential breakthrough in diabetes management, positioning the product as a competitive alternative to existing therapies. Given the increasing prevalence of diabetes and the demand for advanced treatment options, successful outcomes could lead to substantial market opportunities. The collaboration with the Juvenile Diabetes Research Foundation and Oregon Health and Science University enhances credibility and may facilitate further development and commercialization efforts.